For this issue, Luc Zimmer, professor of pharmacology and chair of the Neuropsychopharmacology Committee of the French Society of Pharmacology and Therapeutics (SFPT), talked with Adrian Newman-Tancredi, neuropharmacologist, co-founder and CEO of a biopharmaceutical company developing clinical-stage central nervous system drugs. They address through experiences the particularities of research in neuropsychopharmacology in the pharmaceutical industry. The evolution of drug discovery strategy is also discussed, as well as the reasons for the contrasting landscape of research for new molecules for psychiatry.